Urvi Aras - Concepedia

Author

Urvi Aras

Bristol-Myers Squibb (United States)

Also Known As

L. Ardila, U Aras, U. Aras, Urvi Aras, Urvi Telang Aras

Publications

225

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Roswell Park Comprehensive Cancer Center

About

Urvi Aras is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	53
2	Health Sciences	2	2	28
3	Engineering	1	1	12
4	Natural Sciences	1	1	12
5	Applied Physics	1	1	12

Urvi Aras

Publications

210

Citations

H-Index

Page 1

	Year	Citations
<scp>First‐in‐human</scp> study of deucravacitinib: A selective, potent, allosteric <scp>small‐molecule</scp> inhibitor of tyrosine kinase 2 Ian M. Catlett, Urvi Aras, Lars Hansen, Clinical and Translational Science	2022	52
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data Gerald J. Fetterly, Urvi Aras, Patricia D. Meholick, The Journal of Clinical Pharmacology	2013	35
Chemopreventive and anti‐angiogenic effects of dietary phenethyl isothiocyanate in an <i>N</i>‐methyl nitrosourea‐induced breast cancer animal model Urvi Aras, Yash Gandhi, Patricia A. Masso‐Welch, Biopharmaceutics & Drug Disposition	2012	26
SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2 Ian M. Catlett, Urvi Aras, Y Liu, Annals of the Rheumatic Diseases	2017	21
Model‐Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors Yue Zhao, Kinjal Sanghavi, Amit Roy, Clinical Pharmacology & Therapeutics Surgical OncologyPharmacotherapySystemic ExposuresAdvanced Solid TumorsPhysiologically-based Pharmacokinetic Modeling	2023	15
Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia Gerald J. Fetterly, Urvi Aras, Deepika Lal, The AAPS Journal Hematological MalignancyOncologySequential AfliberceptMedicineAcute Myeloid Leukemia	2013	14
Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (<scp>CheckMate</scp> 040) Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Clinical and Translational Science HepatologyMedicinePharmacologyClinical TrialsDose Selection	2023	13
Performance of the CMS High Granularity Calorimeter prototype to charged pion beams of 20–300 GeV/c Burak Acar, G. Adamov, C. Adloff, Journal of Instrumentation Readout Electronic ComponentsEngineeringPion BeamsHgcal PrototypeAccelerator Physic	2023	12
CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20). Sara Lonardi, Iwona Ługowska, Christopher Jackson, Journal of Clinical Oncology ImmunologyNivo ExposuresCancer Survival ExpectationsPharmacotherapyImmunotherapeutics	2021	11
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects Anjaneya Chimalakonda, Shalabh Singhal, Raymond B. Darbenzio, Clinical Pharmacology in Drug Development	2022	11

Page 1